This Article Full Text Full Text (PDF) All Versions of this Article: 91/4/1246    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Camacho-Hübner, C. Articles by Savage, M. O. Search for Related Content PubMed PubMed Citation Articles by Camacho-Hübner, C. Articles by Savage, M. O. Related Collections Neuroendocrinology and Pituitary Pediatric Endocrinology

Pharmacokinetic Studies of Recombinant Human Insulin-Like Growth Factor I (rhIGF-I)/rhIGF-Binding Protein-3 Complex Administered to Patients with Growth Hormone Insensitivity Syndrome

Department of Endocrinology, William Harvey Research Institute, Queen Mary, University of London (C.C.-H., H.L.S., F.M.-M., M.O.S.), London EC1M 6BQ, United Kingdom; Department of Pediatrics, Birmingham Heartland Hospital (S.R.), Birmingham B9 5SS, United Kingdom; Biochemistry, Endocrinology and Metabolism Unit, Institute of Child Health (M.A.P.), London WC1N 1EH, United Kingdom; Insmed, Inc. (M.S., A.R., G.A., A.S.), Glen Allen, Virginia 23060; Department of Endocrinology and Metabolism and Center of Excellence for Biomedical Research, University of Genoa (F.M.), Genoa I-16132, Italy; and Medical Research Laboratories and Medical Department, Nørrebrogade, Aarhus University Hospital (J.F.), Aarhus DK-8000, Denmark

Address all correspondence and requests for reprints to: Dr. Cecilia Camacho-Hübner, Department of Endocrinology, William Harvey Research Institute, John Vane Science Building, First Floor, Charterhouse Square, London EC1M 6BQ, United Kingdom. E-mail: c.camacho-hubner{at}qmul.ac.uk.

Context: GH insensitivity syndrome (GHIS), Laron syndrome, is characterized by severe short stature, high serum GH levels, and very low serum IGF-I and IGF-binding protein-3 (IGFBP-3) levels associated with a genetic defect of the GH receptor. Recombinant human (rh) IGF-I treatment at doses of 80–120 µg/kg given sc twice daily is effective in promoting growth in these patients. We have investigated a newly developed drug, rhIGF-I/rhIGFBP-3, a 1:1 molar complex of rhIGF-I and rhIGFBP-3.

Objectives: The objectives of the study were to determine IGF-I pharmacokinetics after the administration of rhIGF-I/rhIGFBP-3 in adolescents with GHIS and to evaluate its safety and tolerability.

Design: This was an open-label clinical study.

Setting: The study was conducted in a general pediatric ward of a university teaching hospital.

Participants: Four patients (one female and three males; mean age, 14.9 yr; mean height SD score, –4.9) with confirmed molecular diagnosis of GHIS agreed to participate in the study.

Intervention: rhIGF-I/rhIGFBP-3 was administered in a single sc injection at 0.5 and 1.0 mg/kg·dose (equivalent to 100 and 200 µg/kg rhIGF-I) after breakfast with a 2-d interval between doses.

Results: IGF-I levels reached a maximum between 19 ± 8.3 and 15 ± 6.2 h for the low and high doses, respectively. The circulating IGF-I levels obtained with the low and high doses were similar, although a discrete dose-dependent increase in circulating IGF-I levels was observed. The IGF-I half-life in four subjects after a dose of 0.5 mg/kg rhIGF-I/rhIGFBP-3 was estimated to be 21± 4 h. There were no acute adverse events reported, and all blood glucose measurements were normal.

Conclusion: These data demonstrated that the rhIGF-I/rhIGFBP-3 complex was effective in increasing levels of circulating total and free IGF-I into the normal range for a 24-h period after a single sc administration in patients with GHIS, and that administration of rhIGF-I/rhIGFBP-3 was safe and well tolerated.

This article has been cited by other articles:

				R. G Rosenfeld IGF-I therapy in growth disorders Eur. J. Endocrinol., August 1, 2007; 157(suppl_1): S57 - S60. [Abstract] [Full Text] [PDF]